Taiwan-developed drug to be tested on severe COVID-19 cases in U.S.
06/04/2021 02:02 PM
A drug candidate developed by a Taiwanese company for the treatment of COVID-19 will be administered to seriously ill patients in its Phase II clinical trials in the United States, pending authorization by the relevant authorities, according to the developer Golden Biotechnology Corp.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
KMT to hold assembly on April 26 in protest against President Lai
04/19/2025 01:52 PM - Society
Temperature highs could hit 35°C in southern Taiwan on Saturday
04/19/2025 11:54 AM - Society
Taiwan headline news
04/19/2025 11:24 AM - Society
Watchdog censures Taichung for failing to protect abused migrant caregivers
04/18/2025 09:32 PM - Politics
Lai calls for more trade, tech collaborations with U.S.
04/18/2025 08:54 PM